Walvax Biotechnology (300142.SZ) traded flat 0 % during a 24 hours period ending at 10:29 AM Central Europe on Wednesday 28th. One Walvax Biotechnology stock can currently be bought for about CNY 12.16 on popular exchanges. Current supply of Walvax Biotechnology stocks is 1.6 bn. Walvax Biotechnology has a current market capitalization of CNY 19.3 bn and approximately CNY 481 mn worth of Walvax Biotechnology was traded on exchanges in the last 24 hours. Since last month end, Walvax Biotechnology has traded -11.32 % down. Simple moving average of last 200 days is at CNY 13.04. The highest price of past 52 weeks was recorded at CNY 16.97 on 08/21/2026. 52 weeks low was at CNY 10.88 on 12/31/2025.
Here is how related stocks have performed in the past 24 hours:
Henan Zhongfu Industry (600595.SS) traded flat 0 % and now trades at CNY 5.79. Henan Zhongfu Industry has a market capitalisation of CNY 23 bn. Current price/earnings ratio for Henan Zhongfu Industry is 7.12.
Hainan Jinpan Smart Techno (688676.SS) traded flat 0 % and now trades at CNY 50.26. Current market capitalisation for Hainan Jinpan Smart Techno is CNY 23 bn. Current price/earnings ratio for Hainan Jinpan Smart Techno is 33.84.
Xuji Electric (000400.SZ) traded flat 0 % and now trades at CNY 22.59. Xuji Electric has a market capitalisation of CNY 23.1 bn. Current price/earnings ratio for Xuji Electric is 24.27.
Shenzhen Zhongjin Lingnan (000060.SZ) traded flat 0 % and now trades at CNY 5.14. Shenzhen Zhongjin Lingnan has a market capitalisation of CNY 22.9 bn. Current price/earnings ratio for Shenzhen Zhongjin Lingnan is 15.68.
Simcere Pharmaceutical (2096.HK) traded down -3.04 % and now trades at HKD 10.31. Simcere Pharmaceutical has a market capitalisation of HKD 27 bn. Simcere Pharmaceutical has a current price to earnings ratio of 15.25.
About Walvax Biotechnology
Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, specializes in conducting research and development, production, and sales of bio-medicine products in China. They offer various vaccines, such as those targeting Group A, C meningococcal polysaccharide conjugate for infants from three months to five years preventing diseases like cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for children over the age of two years and adults to prevent diseases caused by the bacterium Neisseria meningitidis groups A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above two years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis groups A, C, Y, and W135. Additionally, they provide haemophilus influenzae type b conjugate vaccine for infants from the age of two months to five years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. The company also offers prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine. Furthermore, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis in individuals from the age of three months to six years; and 23-valent pneumococcal polysaccharide vaccine for children above two years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was established in 2001 and has its main office in Kunming, China. Their website is accessible under www.walvax.com and they are listed on the Shenzhen Stock Exchange. The initial public offering of their stocks took place on November 12, 2010.